GENOTYPING OF POOR METABOLIZERS OF DEBRISOQUINE BY ALLELE-SPECIFIC PCR AMPLIFICATION

被引:495
作者
HEIM, M [1 ]
MEYER, UA [1 ]
机构
[1] UNIV BASEL,BIOCTR,DEPT PHARMACOL,KLINGELBERGSTR 70,CH-4056 BASEL,SWITZERLAND
关键词
D O I
10.1016/0140-6736(90)92086-W
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A method for genotyping poor metabolisers of debrisoquine is based on specific polymerase chain reaction (PCR) amplification of parts of mutant genes for hepatic cytochrome P450IID6. Analysis by restriction fragment length polymorphism allowed identification of only 25% of poor metabolisers, but when it was combined with allele-specific PCR over 95% of poor metabolisers could be identified. The PCR method also allowed the identification of heterozygous carriers of mutant alleles. © 1990.
引用
收藏
页码:529 / 532
页数:4
相关论文
共 22 条
  • [1] METABOLIC OXIDATION PHENOTYPES AS MARKERS FOR SUSCEPTIBILITY TO LUNG-CANCER
    AYESH, R
    IDLE, JR
    RITCHIE, JC
    CROTHERS, MJ
    HETZEL, MR
    [J]. NATURE, 1984, 312 (5990) : 169 - 170
  • [2] RELEVANCE OF GENETIC-POLYMORPHISM IN DRUG-METABOLISM IN THE DEVELOPMENT OF NEW DRUGS
    BALANT, LP
    GUNDERTREMY, U
    BOOBIS, AR
    VONBAHR, C
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 36 (06) : 551 - 554
  • [3] INHIBITORY STUDIES OF MEXILETINE AND DEXTROMETHORPHAN OXIDATION IN HUMAN LIVER-MICROSOMES
    BROLY, F
    LIBERSA, C
    LHERMITTE, M
    DUPUIS, B
    [J]. BIOCHEMICAL PHARMACOLOGY, 1990, 39 (06) : 1045 - 1053
  • [4] CLINICAL-SIGNIFICANCE OF THE SPARTEINE-DEBRISOQUINE OXIDATION POLYMORPHISM
    BROSEN, K
    GRAM, LF
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 36 (06) : 537 - 547
  • [5] CAPORASO N, 1989, CANCER RES, V49, P3675
  • [6] DISPOSITION OF PERPHENAZINE IS RELATED TO POLYMORPHIC DEBRISOQUIN HYDROXYLATION IN HUMAN-BEINGS
    DAHLPUUSTINEN, ML
    LIDEN, A
    ALM, C
    NORDIN, C
    BERTILSSON, L
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 46 (01) : 78 - 81
  • [7] EICHELBAUM M, 1988, ISI ATLAS-PHARMACOL, V2, P243
  • [8] EISENSTEIN BI, 1990, NEW ENGL J MED, V322, P178
  • [9] GAEDIGK A, 1990, NAUNYNSCHMIEDEBERG S, V341, P435
  • [10] GASPARINI P, 1989, NEW ENGL J MED, V320, P809